


**AMENDMENTS TO THE CLAIMS:**

1. -11. (Canceled)

12. (Withdrawn) A composition comprising a therapeutically effective amount of the naphthoquinone derivative of Formula 1 for the treatment of *Mycobacterium tuberculosis*, wherein the Formula 1 comprises:




wherein,

R represents an OH group;


R1 represents a methyl group;

R2 and R3 each independently represent hydrogen or a group selected from:









wherein R and R1 are as defined above; and

R4 represents hydrogen or a group selected from:



or pharmaceutically acceptable salts thereof, in the treatment and/or control of tuberculosis in a patient caused by *Mycobacterium tuberculosis*.







NVA293920.1

12

wherein the naphthoquinone derivative of Formula 1 is a compound of Formula 1a or Formula 1b:



Formula 1a




Formula 1b

or pharmaceutically acceptable salts thereof, in the treatment and/or control of tuberculosis in a patient caused by *Mycobacterium tuberculosis* wherein R and R1 are as defined for Formula 1 in claim 12.

14. (Withdrawn) A composition according to claim 12 wherein the naphthoquinone derivative of Formula 1 is 5,5' dihydroxy 7,7' binaphthoquinone (diospyrin) or 5-hydroxy-7-methyl-1,4-naphthoquinone (7-methyljuglone), or a mixture thereof.

15. (Withdrawn) A method of preparing a medicament for use in treating and/or controlling tuberculosis in a patient caused by *Mycobacterium tuberculosis* comprising the step of:

formulating a composition with a therapeutically effective amount of a naphthoquinone derivative having the Formula 1:




wherein,

R represents an OH group;


R1 represents a methyl group;

R2 and R3 each independently represent hydrogen or a group selected from:



wherein R and R1 are as defined above; and

R4 represents hydrogen or a group selected from:




wherein R and R1 are as defined above,

or pharmaceutically acceptable salts thereof.

16. (Withdrawn) A method of preparing a medicament for use in treating and/or controlling tuberculosis in a patient caused by *Mycobacterium tuberculosis* comprising the step of:

formulating a composition with a therapeutically effective amount of a

naphthoquinone derivative having the Formula 1:




wherein,

R represents an OH group;


R1 represents a methyl group;

R2 and R3 each independently represent hydrogen or a group selected from:



wherein R and R1 are as defined above; and


R4 represents hydrogen or a group selected from:




wherein R and R1 are as defined above, and ~~The method of preparing a medicament according to claim 15~~

wherein the naphthoquinone derivative of Formula 1 is a compound of Formula 1a or Formula 1b:

-7-



Formula 1a




Formula 1b

or pharmaceutically acceptable salts thereof ~~wherein R and R1 are as defined for Formula 1 in claim 15.~~

17. (Withdrawn) The method of preparing a medicament according to claim 15 wherein the naphthoquinone derivative of Formula 1 is 5,5' dihydroxy 7,7' binaphthoquinone (diospyrin) or 5-hydroxy-7-methyl-1,4-naphthoquinone, or a mixture thereof.

18. (Previously presented) A method of treating and/or controlling tuberculosis caused by *Mycobacterium tuberculosis* comprising:  
administering to a patient in need thereof a therapeutically effective amount of a naphthoquinone derivative having the Formula 1:

-8-




wherein,

R represents an OH group;


R1 represents a methyl group;

R2 and R3 each independently represent hydrogen or a group selected from:



wherein R and R1 are as defined above; and

R4 represents hydrogen or a group selected from:




wherein R and R1 are as defined above,

or pharmaceutically acceptable salts thereof.

19. (Currently amended) A method of treating and/or controlling tuberculosis caused by *Mycobacterium tuberculosis* comprising:  
administering to a patient in need thereof a therapeutically effective amount of a naphthoquinone derivative having the Formula 1:

-9-




wherein,

R represents an OH group;


R1 represents a methyl group;

R2 and R3 each independently represent hydrogen or a group selected from:




wherein R and R1 are as defined above; and

R4 represents hydrogen or a group selected from:




wherein R and R1 are as defined above, and ~~A method according to claim 18~~

wherein the naphthoquinone derivative of Formula 1 is a compound of Formula 1a or Formula 1b:



Formula 1a





Formula 1b

or pharmaceutically acceptable salts thereof wherein R and R1 are as defined for  
~~Formula 1 in claim 18.~~

20. (Previously presented) A method according to claim 18 wherein the naphthoquinone derivative of Formula 1 is 5,5' dihydroxy 7,7' binaphthoquinone (diospyrin) or 5-hydroxy-7-methyl-1,4-naphthoquinone (7-methyljuglone), or a mixture thereof.

21. (Previously presented) A method according to claim 18 wherein the naphthoquinone derivative of Formula 1 is administered orally, intravenously, intramuscularly or transdermally.